Outpace Bio Raises $144M for Cancer Treatment Innovations

Outpace Bio raises $144M in Series B Financing

Outpace Bio (Linkedin), a leader in AI-powered protein design for enhanced T cell therapies, secured $144M in Series B financing. With a total capital raised of approximately $200M, Outpace Bio is revolutionizing cancer treatment for patients with solid tumors.

Funding Amount: $144 million

Industry: Biotechnology Research

Employee Count: 51-200

CEO: Marc Lajoie (CEO Linkedin)

What Outpace Bio needs to buy: Outpace Bio is seeking partnerships with clinical research organizations (CROs) for advancing their therapies through clinical trials. Additionally, they are looking for collaborations with biotech manufacturers to produce engineered T cell therapies. Marketing firms that specialize in healthcare outreach can also support Outpace Bio in effectively communicating their innovative solutions to healthcare providers and patients.